LEWISVILLE, Texas -- (Business Wire)
As previously disclosed, Orthofix International N.V. (NASDAQ: OFIX) (the
“Company”) participated in a hearing before a NASDAQ Hearings Panel (the
“Hearings Panel”) on October 2, 2014 in connection with the Company’s
non-compliance with NASDAQ Listing Rule 5250(c)(1) due to the delayed
filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended
June 30, 2014, and the Company’s anticipated financial restatement
relating to prior periods.
At the hearing, the Company requested that the Hearings Panel grant the
Company through January 15, 2015 to make these filings, as well as the
Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended
September 30, 2014 (the “2014 Third Quarter Form 10-Q”), though the 2014
Third Quarter Form 10-Q was not yet due as of the hearing date under the
rules of the Securities and Exchange Commission (the “SEC”).
On October 9, 2014, the Company received a decision letter from NASDAQ’s
Office of General Counsel stating that the Hearings Panel had granted
the Company’s request and, accordingly, the Company’s common stock would
continue to trade on the NASDAQ Stock Market provided that the Company
becomes current in its periodic filings with the SEC on or before
January 15, 2015.
On November 19, 2014, the Company received an anticipated letter from
NASDAQ noting that the 2014 Third Quarter Form 10-Q had not been filed
by its due date with the SEC on November 10, 2014 and, as such,
represented an additional basis for non-compliance with Listing Rule
5250(c)(1).
The Company continues to work to complete the procedures needed to file
its two delayed quarterly reports, as well as the amended reports
containing its restatement for prior periods. As requested by the letter
from NASDAQ, the Company will be providing a written update to the
Hearings Panel regarding these matters on November 25, 2014.
About Orthofix
Orthofix International N.V. is a diversified, global medical device
company focused on improving patients’ lives by providing superior
reconstructive and regenerative orthopedic and spine solutions to
physicians worldwide. Headquartered in Lewisville, TX, the company has
four strategic business units that include BioStim, Biologics, Extremity
Fixation and Spine Fixation. Orthofix products are widely distributed
via the company’s sales representatives, distributors and subsidiaries.
In addition, Orthofix is collaborating on research and development
activities with leading clinical organizations such as the
Musculoskeletal Transplant Foundation and the Texas Scottish Rite
Hospital for Children. For more information, please visit www.orthofix.com.
Forward-Looking Statements
This communication contains certain forward-looking statements under the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements, which may include, but are not limited to, statements
concerning the projections, financial condition, results of operations
and businesses of Orthofix and its subsidiaries and are based on
management’s current expectations and estimates and involve risks and
uncertainties that could cause actual results or outcomes to differ
materially from those contemplated by the forward-looking statements.
The forward-looking statements in this release do not constitute
guarantees or promises of future performance. Factors that could cause
or contribute to such differences may include, but are not limited to,
risks relating to the uncertain results and timing of our anticipated
filing of restated financial statements for prior periods, the
anticipated magnitude and nature of error corrections reflected by such
filings, the timing of the filing of our late quarterly reports on Form
10-Q, potential delisting of our securities from the Nasdaq Stock
Market, as well how these matters may impact our expenses, liquidity,
legal liability, borrowing ability, product sales, relationships with
customers, suppliers, strategic partners and third party reimbursement
providers, ongoing compliance obligations under our corporate integrity
agreement with the Office of Inspector General of the Department of
Health and Human Services, deferred prosecution agreement with the U.S.
Department of Justice and consent decree with the SEC, ability to remain
in compliance with covenants and other obligations under our senior
secured credit agreement, the cost and nature of our insurance coverage,
and other factors described in our annual report on Form 10-K for the
fiscal year ended December 31, 2013 and other subsequent periodic
reports filed by the Company with the SEC. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Contacts:
Orthofix International N.V.
Mark Quick, 214-937-2924
Investor
Relations
markquick@orthofix.com
or
Denise
Landry, 214-937-2529
Media Relations
deniselandry@orthofix.com
Source: Orthofix International N.V.
© 2024 Canjex Publishing Ltd. All rights reserved.